We're Horizon, a global biotechnology company driven by a simple idea: we believe that science and compassion must work together to transform lives.
INVESTOR RELATIONS CONTACTS ; Dan Trolio Executive Vice President & CFO (860) 674-9977 dtrolio@horizontechfinance.com. ICR Group Garrett Edson Managing Director
Missing: hznp | Show results with:hznp
Amgen Investor Presentation December 2023 1.8 MB. 10.31.2023. Q3 2023 Earnings Presentation 1.8 MB. 10.24.2023. Hematology/Oncology Update ESMO Presentation 5.7 ...
... ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF ... HZNP. The Nasdaq Global Select Market. Securities ... investor is treated as a United States shareholder ...
People also ask
Is Amgen buying Horizon Therapeutics?
How much did the Hznp merger cost?
Does Horizon Therapeutics still exist?
Who owns Horizon Pharma?
Aug 8, 2023 · This earnings press release, investor deck and the related Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 are publicly ...
Jul 17, 2023 · Investor Relations: Tina Ventura Senior Vice President, Chief Investor Relations Officer Investor-relations@horizontherapeutics.com. U.S. ...
The Company markets 11 medicines through its orphan, rheumatology and primary care business units. Visit website. REPORT RATINGS. 4.8 / 5.0 (62). Horizon Pharma ...
... shares are admitted to trading on Nasdaq under the ticker "HZNP". ... Investor Relations, by email to ir@horizontherapeutics.com. ... financial-information/sec ...
May 3, 2023 · ... HZNP) today announced first-quarter 2023 financial results. “We ... Chief Investor Relations Officer, Corporate Affairs & Chief Communications ...
... (HZNP) CEO Tim Walbert on Q3 2019 Results - Earnings Call Transcript · SA TranscriptsWed, Nov. 06, 2019. Horizon Pharma plc (HZNP) Investor Presentation - ...
Missing: relations | Show results with:relations